AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00467688 — intervention group
Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Real time access to current glucose values during CGMS
Description: One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
Study NCT02717234 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nutrition Supplement
Description: Oral nutrition supplement intended for consumption at 3 servings per day
Study NCT02717234 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Supplement
Description: Oral nutrition supplement intended for consumption at 3 servings per day
Study NCT03564808 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC
Description: Adipose tissue enriched with mesenchymal stem cells
Study NCT03871777 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
Study NCT03871777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo mouthwash
Description: Participants received placebo mouthwash (ultrapure unflavoured water) with which they rinsed their mouth for one minute, twice a day for 7 days. Resting metabolic rate and blood pressure were measured on day eight. Additionally, blood and saliva samples were taken from all the participants. Dietary records of seven days were also collected in order to confirm the foods and portion sizes consumed, preparation methods, recipes and any brand names.
Study NCT03871777 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
Study NCT03871777 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: After using placebo and complete all the physiological measurements, participants were given a further one-week supply of antibacterial mouthwash containing 0.2% chlorhexidine (Corsodyl, GlaxoSmithKline, UK), encouraged to rinse their mouth for one minute, twice a day for 7 more days. They returned to the laboratory in 7 days to repeat all measurements in the same order.
Study NCT04634422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma exchange and convalescent plasma
Description: In addition to standard care, participants will receive 2 plasma exchange procedures max. 30 hours apart using the membrane or centrifuge method. PLEX will be initiated within 30 hours of randomization. The exchange volume of 60 mg of plasma per kg body weight will be substituted with albumin 5% and Ringer/saline 50% at the beginning followed by 50% FFP towards the end of the procedure. At the end of the 2nd procedure, participants will receive additional 2 units of CCP (equalling 600 ml CCP) with an administration rate of 100 to 250 ml/hr. Anticoagulation may be provided by citrate or by heparin but it is suggested that in patients with active bleeding regional citrate anticoagulation be utilized. PLEX may be performed via a central venous catheter if patient is deemed unsuitable for peripheral venous access, the latter is recommended. Possible SAE related to PLEX+CCP will be recorded as air embolism, anaphylaxis, TRALI and reported as an outcome.
Study NCT03413891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Mouthwash
Study NCT03413891 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mouthwash
Study NCT03842358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand-held hybrid probe
Description: Consists of a commercially available US transducer located in the middle and near-infrared source and detector optical fibers distributed at the periphery
Study NCT04123470 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delolimogene mupadenorepvec
Description: LOAd703 is an oncolytic adenovirus encoding TMZ-CD40L and 4-1BBL
Study NCT04123470 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: atezolizumab
Description: Atezolizumab is an anti-PD-L1 antibody
Study NCT03649880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ¹⁸F-Fluoromisonidazole
Description: Given IV
Study NCT03649880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT
Study NCT03649880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI or PET/CT
Study NCT03649880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT03649880 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen Therapy
Description: Receive supplemental oxygen
Study NCT04137952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: size of error visual feedback
Description: The strategies are expected to enhance opportunities of error experience and motor exploration via modified visual feedback, underlying facilitations of attentional resource and error-related neural networks.
Study NCT03635892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabozantinib
Description: cabozantinib 40mg, self administered orally once daily on a continuous schedule (days 1-28) Patients will continue to take cabozantinib until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
Study NCT03635892 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Patients will receive an intravenous infusion of nivolumab, per institutional standards, at 240 mg on Cycle 1, Day 1 and will return to the center approximately every two weeks (14 ± 3 days) for subsequent infusions until disease progression (unless continuing treatment beyond progression), major toxicity, or withdrawal from the study for any reason.
Study NCT04139733 — intervention group
Intervention type: PROCEDURE
Intervention: Prone positon
Description: Prone position within 24 hours after VV-ECMO support. Prone position for at least conservative hours per day for a minimum of 5 days.
Study NCT04139733 — intervention group
Intervention type: PROCEDURE
Intervention: Supine positon
Description: Conventional supine position ventilation, no prone position.
Study NCT03712813 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrodyne LivMD plate
Description: Synchronous (applied to both feet) low intensity vibration for 10 minutes, twice daily for 12 months.
Study NCT03818256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miricorilant
Description: Miricorilant 600 mg (6 X 100 mg tablets) for once-daily oral dosing
Study NCT03818256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for once-daily oral dosing
Study NCT03587961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symdeko
Description: explore the use of off-label CFTR modulators that may affect CFTR function in patients with CFTR mutations that are not currently approved for these drugs.
Study NCT04540393 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD1222
Description: Participants will receive 2 doses of AZD1222; the first dose will be administered on Day 1 and the second dose on Day 29. Unit dose strength(s) > 0.7 × 1011 vp/mL. Dosage level(s) 5 ×1010 vp (nominal). Route of administration Intramuscular injection
Study NCT02715609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Study NCT02715609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Gluconate
Study NCT03534401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARCHES Kenya
Description: ARCHES: Contraceptive counselors in intervention clinics will receiving training to ) provide counseling and education regarding risk of partner detection of contraceptive methods, and women's and girls' strategies to use contraceptive methods to minimize partner detection risk integrated into standard contraceptive counseling, b) make brief inquiries to allow clients the opportunity to disclose experiences of RC and IPV (i.e., screening), c) provide method-specific counseling based on this information and the method chosen by the client, d) provide supported linkage of IPV survivors to local IPV support services (i.e. warm referral), and e) offer palm-sized educational materials on RC and IPV, as well as IPV services to all clients.
Study NCT03768804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SyncAV algorithm on
Description: Cardiac Resynchronisation Device will be set to have the SyncAV algorithm on for the duration of the cardiopulmonary exercise test (CPET), before being reset to pre-existing settings
Study NCT03768804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SyncAV algorithm off
Description: ardiac Resynchronisation Device will be set to have the SyncAV algorithm off and a fixed AV delay, for the duration of the CPET, before being reset to pre-existing settings
Study NCT01939665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife Irreversible electroporation (IRE)
Description: Tumor ablation with irreversible electroporation with the NanoKnife
Study NCT03404687 — intervention group
Intervention type: RADIATION
Intervention: ultrasound
Description: for assessment of adnexal masses size and pattern
Study NCT02715609 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02715609 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Study NCT02715609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Study NCT02818907 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Additional biological samples
Description: blood and tumor tissue samples
Study NCT01607957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Study NCT01607957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
Study NCT03582475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03582475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03582475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT03582475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT03582475 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01899521 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
Study NCT01899521 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bronchoscopy
Description: Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
Study NCT01899521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc sulfate 220 mg once daily
Study NCT01899521 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: S-adenosylmethionine 400 mg twice daily
Study NCT04042441 — intervention group
Intervention type: DRUG
Intervention: Insulin Degludec/Insulin Aspart
Description: Insulin Degludec/Insulin Aspart (Ryzodeg®) as prescribed by the patient's treating physician. The decision to initiate or switch into treatment with commercially available Ryzodeg® has been made before, and independently from, the decision to include the patient in this study.
Study NCT02753270 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short catheter
Description: Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
Study NCT02753270 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Long catheter preceded by tumescence
Description: Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
Study NCT00734149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Study NCT00734149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Study NCT00734149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract
Description: 2 capsules each day containing a total of 500 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa extract placebo
Description: Cocoa extract placebo
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT02422745 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single lowest dose of STSP-0601 for Injection following protocol requirements
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single low dose of STSP-0601 for Injection following protocol requirements
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single low-intermediate dose of STSP-0601 for Injection following protocol requirements
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single intermediate dose of STSP-0601 for Injection following protocol requirements
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single high dose of STSP-0601 for Injection following protocol requirements
Study NCT04747964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STSP-0601 for Injection
Description: Subjects will receive one single highest dose of STSP-0601 for Injection following protocol requirements
Study NCT04179175 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks
Study NCT04179175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks
Study NCT04179175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 2 weeks
Study NCT04179175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 4 weeks
Study NCT04179175 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: secukinumab
Description: secukinumab 300mg every 4 weeks
Study NCT01652235 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study NCT04559815 — intervention group
Intervention type: DRUG
Intervention: Oral Semaglutide
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Study NCT06547684 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fESWT
Description: Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle.
Study NCT06547684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fESWT
Description: Shock wave therapy will be applied with Duolith SD1 device (Storz Medical, Tagerwilen, Switzerland). Therapy will be administered in the gastrocnemius medial and lateral and in the soleus muscles.~Parameters: 0.15mJ/mm2, 4-5 Hz, 1500 shoots/muscle.
Study NCT04282187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Given IV
Study NCT04282187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Given PO
Study NCT04282187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fedratinib
Description: Given PO
Study NCT04282187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04282187 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Given PO
Study NCT04315948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: The lyophilized formulation of Remdesivir is a preservative-free, white to off-white or yellow, lyophilized solid containing 100 mg of Remdesivir to be reconstituted with 19 mL of sterile water for injection and diluted into IV infusion fluids prior to IV infusion. Following reconstitution, each vial contains a 5 mg/mL Remdesivir concentrated solution with sufficient volume to allow withdrawal of 20 mL (100 mg of remdesivir). It is supplied as a sterile product in a single-use, 30 mL, Type 1 clear glass vial.
Study NCT04315948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: The oral tablets of lopinavir/ritonavir contain 200 mg lopinavir, 50 mg ritonavir. They have a yellow colour, film-coated, ovaloid shape debossed with the a logo and the code KA. The oral solution for patients who cannot swallow is a light yellow to orange colored liquid containing 400 mg lopinavir and 100 mg ritonavir per 5 mL (80 mg lopinavir and 20 mg ritonavir per mL).
Study NCT04315948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta-1A
Description: IFN-ß-1a is supplied as a sterile solution containing no preservative available in a prefilled syringe. It will be provided as a single-dose prefilled graduated syringe with 44 µg per 0.5 mL. The liquid should be clear to slightly yellow. Do not use if the liquid is cloudy, discolored or contains particles. Use a different syringe.
Study NCT04315948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine is supplied as film-coated 200 mg tablets. Hydroxychloroquine sulfate tablets are presented as white or whitish, peanut-shaped, oblong or round film-coated tablets containing 200 mg of hydroxychloroquine sulfate (equivalent to 155 mg base).
Study NCT04315948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care
Study NCT04315948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04315948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: AZD7442 will be supplied as separate vials of AZD8895 and AZD1061 containing 150 mg colorless to slightly yellow, clear to opalescent solutions for injection.
Study NCT04315948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Since April, 2021, the placebo will be a 0.9% (w/v) NaCl solution for infusion also called saline. The placebo will be supplied as a single 10-mL, clear and colorless vial.
Study NCT03043794 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy SBRT
Description: Stereotactic Body Radiation Therapy to the breast to 21 Gy
Study NCT04410978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolebrutinib
Description: Pharmaceutical form: Tablet~Route of administration: Oral
Study NCT04410978 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide HMR1726
Description: Pharmaceutical form: Tablet~Route of administration: Oral